Adverse events after colonoscopy in a randomised colorectal cancer screening trial.
Humans
Male
Female
Colorectal Neoplasms
/ diagnosis
Colonoscopy
/ adverse effects
Middle Aged
Early Detection of Cancer
/ methods
Aged
Norway
/ epidemiology
Cross-Sectional Studies
Risk Factors
Sigmoidoscopy
/ adverse effects
Occult Blood
Gastrointestinal Hemorrhage
/ epidemiology
Abdominal Pain
/ etiology
Colonoscopy
Colorectal cancer screening
Epidemiology
Journal
BMJ open gastroenterology
ISSN: 2054-4774
Titre abrégé: BMJ Open Gastroenterol
Pays: England
ID NLM: 101660690
Informations de publication
Date de publication:
07 Oct 2024
07 Oct 2024
Historique:
received:
23
05
2024
accepted:
19
09
2024
medline:
8
10
2024
pubmed:
8
10
2024
entrez:
7
10
2024
Statut:
epublish
Résumé
Colonoscopy-related adverse events increase the burden of colorectal cancer (CRC) screening. This cross-sectional study evaluates adverse events during and after colonoscopy in a large, randomised CRC screening trial in Norway comparing sigmoidoscopy to immunochemical testing for faecal blood. We included all individuals who underwent colonoscopy at two screening centres between 2012 and 2020. From medical records, we retrieved data on adverse events during and within 30 days after colonoscopy and classified them according to the American Society for Gastrointestinal Endoscopy lexicon for endoscopic adverse events. Multivariable logistic regression models were fitted to identify risk factors for adverse events. Of the 10 244 included individuals, 242 (2.4%) had at least one adverse event that was possibly, probably, or definitively related to the colonoscopy. 188 (1.8%) had mild adverse events, 50 (0.49%) had moderate, 3 (0.03%) had severe, and 1 had a fatal adverse event. The most frequent adverse events were lower gastrointestinal bleeding (0.86%), abdominal pain (0.48%), vasovagal reaction (0.39%), postpolypectomy syndrome (0.20%), and perforation (0.08%). 23 (0.22%) individuals had non-gastrointestinal adverse events. Risk factors associated with adverse events were older age, female sex, screening centre, anticoagulant therapy, number of polypectomies, size of lesion removed, presence of proximal lesion, and adenocarcinoma. Adverse event rates per endoscopist ranged from 0% to 4.9%. Adverse events after colonoscopy of screening positives occurred in about 2 out of 100 procedures. Three-quarters of events were mild. Awareness of risk factors may help endoscopists to mitigate the risk. NCT01538550.
Identifiants
pubmed: 39375173
pii: bmjgast-2024-001471
doi: 10.1136/bmjgast-2024-001471
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT01538550']
Types de publication
Journal Article
Randomized Controlled Trial
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: The bowel preparation used for colonoscopy was provided free of charge by Ferring Pharmaceuticals. SOF reports Chairman, The Norwegian Society of Clinical Nutrition and Metabolism; Council Member, European Society for Clinical Nutrition and Metabolism outside of the submitted work.